William Drohan | Academic Influence

William Drohan's AcademicInfluence.com Rankings

William Drohan

Biology

#3641

World Rank

#5533

Historical Rank

#1460

USA Rank

Microbiology

#426

World Rank

#480

Historical Rank

#111

USA Rank

biology Degrees

Download Badge

Biology

William Drohan's Degrees

PhD Microbiology Stanford University
Masters Biology Stanford University
Bachelors Biology Stanford University

Similar Degrees You Can Earn

Why Is William Drohan Influential?

(Suggest an Edit or Addition)

According to Wikipedia, William N. Drohan was an American microbiologist and academic known for his research in the field of hematology. Education Drohan earned a Bachelor of Arts degree in bacteriology from the University of California, Los Angeles and a PhD in medical microbiology and immunology from UCLA School of Medicine.

(See a Problem?)

William Drohan's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Human endothelial cell growth factor: cloning, nucleotide sequence, and chromosome localization. (1986) (611)
The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy (1998) (310)
Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt‐Jakob disease in humans (1999) (292)
Altered levels of laminin receptor mRNA in various human carcinoma cells that have different abilities to bind laminin. (1986) (244)
High-level expression of a heterologous protein in the milk of transgenic swine using the cDNA encoding human protein C. (1992) (166)
Similar levels of infectivity in the blood of mice infected with human‐derived vCJD and GSS strains of transmissible spongiform encephalopathy (2003) (160)
Enhanced endothelialization of expanded polytetrafluoroethylene grafts by fibroblast growth factor type 1 pretreatment. (1992) (140)
An angiogenic growth factor is expressed in human glioma cells. (1987) (138)
Transgenic pigs produce functional human factor VIII in milk (1997) (137)
Experimental analysis by site-directed mutagenesis of somatic mutation effects on affinity and fine specificity in antibodies specific for lysozyme. (1992) (137)
Detection and cloning of human DNA sequences related to the mouse mammary tumor virus genome. (1982) (127)
Fibrin sealant: current and potential clinical applications. (1996) (122)
Production of functional human α1-antitrypsin by plant cell culture (1999) (121)
Effective use of optimized, high-dose (50 kGy) gamma irradiation for pathogen inactivation of human bone allografts. (2005) (103)
FGF-1 affixation stimulates ePTFE endothelialization without intimal hyperplasia. (1994) (99)
Expression and Purification of Functional Human α‐1‐Antitrypsin from Cultured Plant Cells (2001) (98)
Modulation of the sis gene transcript during endothelial cell differentiation in vitro. (1985) (93)
cDNA clones reveal differences between human glial and endothelial cell platelet-derived growth factor A-chains (1987) (80)
Hemostatic efficacy of a fibrin sealant-based topical agent in a femoral artery injury model: a randomized, blinded, placebo-controlled study. (1997) (73)
High‐dose gamma irradiation for soft tissue allografts: High margin of safety with biomechanical integrity (2006) (71)
Effective use of gamma irradiation for pathogen inactivation of monoclonal antibody preparations. (2002) (68)
Novel class of mouse mammary tumor virus-related DNA sequences found in all species of Mus, including mice lacking the virus proviral genome. (1982) (65)
Implications of new dry fibrin sealant technology for trauma surgery. (1997) (64)
Inactivation of viral and prion pathogens by γ‐irradiation under conditions that maintain the integrity of human albumin (2003) (64)
Proteolytic maturation of protein C upon engineering the mouse mammary gland to express furin. (1995) (55)
Production of Biologically Active Human Protein C in the Milk of Transgenic Mice a (1992) (54)
Blood proteins from transgenic animal bioreactors. (1996) (52)
A three-dimensional model of an anti-lysozyme antibody. (1987) (52)
Biological equivalence of natural bovine and recombinant human alpha-endothelial cell growth factors. (1987) (51)
Utilization of an Epstein-Barr virus replicon as a eukaryotic expression vector. (1988) (51)
Comparative study of the efficacy of the common topical hemostatic agents with fibrin sealant in a rabbit aortic anastomosis model. (2002) (49)
Isolation of the mouse mammary tumor virus sequences not transmitted as germinal provirus in the C3H and RIII mouse strains (1977) (47)
Transgenic pigs as bioreactors: a comparison of gamma-carboxylation of glutamic acid in recombinant human protein C and factor IX by the mammary gland. (1999) (47)
Haemophilia and advanced fibrin sealant technologies (1998) (43)
Conformational changes in an epitope localized to the NH2-terminal region of protein C. Evidence for interaction of protein C domains. (1989) (43)
Optimizing human demineralized bone matrix for clinical application. (2000) (41)
Production of functional human alpha 1-antitrypsin by plant cell culture. (1999) (40)
Expression and purification of functional human alpha-1-Antitrypsin from cultured plant cells. (2001) (38)
Recombinant Human Protein C Expression in the Milk of Transgenic Pigs and the Effect on Endogenous Milk Immunoglobulin and Transferrin Levels (2004) (38)
Transgenic livestock as drug factories. (1997) (38)
Distribution of Deoxyribonucleic Acid Complementary to the Ribonucleic Acid of Avian Myeloblastosis Virus in Tissues of Normal and Tumor-Bearing Chickens (1972) (38)
Effect of fibrin glue and opsite on open wounds in DB/DB mice. (1993) (37)
Assessment of topical hemostats in a renal hemorrhage model in heparinized rats. (2001) (37)
Delivery of Demineralized Bone Powder by Fibrin Sealant (1995) (36)
Failure of immunocompetitive capillary electrophoresis assay to detect disease‐specific prion protein in buffy coat from humans and chimpanzees with Creutzfeldt‐Jakob disease (2003) (36)
Protein C and related anticoagulants (1990) (33)
Physical and biochemical characterization of five commercial resins for immunoaffinity purification of factor IX. (1992) (33)
Structural differences among monoclonal antibodies with distinct fine specificities and kinetic properties. (1999) (32)
New methods for inactivation of lipid‐enveloped and nonenveloped viruses (1998) (32)
Transgene detection in mouse tail digests. (1994) (31)
Mason-Pfizer virus RNA genome: relationship to the RNA of morphologically similar isolates and other oncornaviruses (1976) (30)
Phenotypic and genotypic stability of multiple lines of transgenic pigs expressing recombinant human protein C (1997) (29)
The Porcine Mammary Gland as a Bioreactor for Complex Proteinsa (1994) (29)
Affinity purification of biologically active and inactive forms of recombinant human protein C produced in porcine mammary gland (1996) (28)
Proteolytic processing of human protein C in swine mammary gland. (1995) (28)
Distribution of Mason-Pfizer Virus-Specific Sequences in the DNA of Primates (1977) (28)
Development of an Immunoaffinity Process for Factor IX Purification (1990) (27)
Thermal Stability and Domain-Domain Interactions in Natural and Recombinant Protein C (*) (1995) (27)
Process Implications for Metal‐Dependent Immunoaffinity Interactions (1989) (26)
Effect of matrices on affinity purification of protein C (1992) (26)
Gene transfer efficiency during gestation and the influence of co-transfer of non-manipulated embryos on production of transgenic mice (2005) (25)
Stable expression of recombinant factor VIII molecules using a bovine papillomavirus vector. (1987) (23)
Mouse Mammary Tumor Virus Proviral Sequences Congenital to C3H/Sm Mice Are Differentially Hypomethylated in Chemically Induced, Virus-Induced, and Spontaneous Mammary Tumors (1982) (22)
Preliminary study of biosensor optimization for the detection of protein C. (1998) (21)
Development of an animal model for assessment of the hemostatic efficacy of fibrin sealant in vascular surgery. (2001) (21)
Rate Limitations in Posttranslational Processing by the Mammary Gland of Transgenic Animals a (1996) (20)
In vitro development of zygotes from prepubertal gilts after microinjection of DNA. (1992) (19)
Comparative study of the hemostatic efficacy of a new human fibrin sealant: is an antifibrinolytic agent necessary? (2002) (18)
Effect of feed flow-rate, antigen concentration and antibody density on immunoaffinity purification of coagulation factor IX. (1990) (17)
Inefficient processing of human protein C in the mouse mammary gland (1994) (17)
Isolation and characterization of a new mouse mammary tumor virus from BALB/c mice. (1981) (17)
Differences in mouse mammary tumor viruses: Relationship to early and late occurring mammary tumors (1977) (17)
Novel delivery systems for coagulation proteins (1998) (16)
Inactivation of lipid‐enveloped and non‐lipid‐enveloped model viruses in normal human plasma by crosslinked starch‐iodine (1994) (16)
Iodine-mediated inactivation of lipid- and nonlipid-enveloped viruses in human antithrombin III concentrate. (1995) (15)
Metabolic and hemodynamic effects of CO2 pneumoperitoneum in a controlled hemorrhage model. (2001) (15)
Functional integrity of intravenous immunoglobulin following irradiation with a virucidal dose of gamma radiation. (2004) (15)
Controlled gamma-irradiation mediated pathogen inactivation of human urokinase preparations with significant recovery of enzymatic activity. (2003) (15)
A Scalable Method for the Purification of Recombinant Human Protein C from the Milk of Transgenic Swine (1994) (14)
Viral inactivation of vesicular stomatitis virus in normal human serum by cross-linked polyvinylpyrrolidone. (1993) (13)
Protein C detection via fluorophore mediated immuno-optical biosensor. (1997) (13)
The Expression of Therapeutic Proteins in Transgenic Animals (1991) (12)
RNA of simian sarcoma-associated virus type 1 produced in human tumor cells (1975) (12)
N-GLYCAN SIALYLATION IS IMPORTANT FOR IN VIVO RECOVERY OF RECOMBINANT FACTOR IX (2007) (12)
Activation of recombinant human protein C. (1996) (12)
Diversity of mammary tumor viral genes within the genus Mus, the species Mus musculus, and the strain C3H (1979) (11)
Strategy for purification of coagulation factor concentrates. (1989) (10)
Polymorphism associated with the human coagulation factor X (F10) gene. (1985) (10)
Large‐Scale Production and Properties of Immunoaffinity‐Purified Human Activated Protein C Concentrate (1995) (10)
Recombinant Technology in Hemostasis and Thrombosis (2012) (9)
In vitro studies on the effect of activated protein C on platelet activation and thrombin generation. (1997) (9)
Isolation of a cDNA clone for the human laminin-B1 chain and its gene localization. (1987) (9)
Evaluation of systems for collection of porcine zygotes for DNA microinjection and transfer. (1992) (8)
Effect of gamma irradiation on the structural stability and functional activity of plasma-derived IgG. (2015) (8)
Isolation and sequencing of a cDNA clone homologous to the v-sis oncogene from human endothelial cells (1986) (8)
Evaluation of CNBr, FMP and hydrazide resins for immunoaffinity purification of factor IX. (1992) (8)
Gene Quantification (1998) (8)
Purification of antithrombin III (human). (1991) (7)
Reusable, real-time, immuno-optical protein C biosensor. (1997) (7)
Differential Distribution of Mouse Mammary Tumor Virus-Related Sequences in the DNA’s of Rats (1979) (7)
DIVERSITY OF MOUSE MAMMARY TUMOR VIRUS GENETIC INFORMATION AND GENE PRODUCTS IN RODENTS (1978) (6)
Interspersion of sequences in avian myeloblastosis virus rna that rapidly hybridize with leukemic chicken cell DNA (1975) (6)
Optimizing gene expression in BPV-transformed cells: effects of cell type on enhancer/promoter interaction. (1987) (6)
The use of molecular hybridization to track the mode of transmission and distribution of murine mammary tumor viruses: a model for etiologic studies of human breast cancer. (1978) (5)
Progress in transgenic production of human plasma proteins in mammary bioreactors (2000) (5)
PRODUCTION OF HUMAN THERAPEUTIC PROTEINS IN TRANSGENIC ANIMALS (1994) (5)
Separation of recombinant human protein C from transgenic animal milk using immobilized metal affinity chromatography. (1997) (4)
Reusability study of fiber optic based protein C biosensor. (1999) (4)
Correlation between the detection of specific mouse mammary tumor proviral sequences and the presence of pulmonary metastases in mice bearing spontaneous mammary tumors. (1980) (3)
Gamma irradiation of intravenous immunoglobulin. (2004) (3)
The use of standard and relaxed hybridization conditions to detect two classes of sequences related to type-D retroviruses in the DNAs of primates. (1978) (3)
Use of molecular hybridization to detect type D retrovirus markers in rhesus placentas and other tissues. (1979) (3)
Characterization of a retrovirus isolated from normal mink cells co-cultivated with a dog mammary tumour. (1979) (2)
Separation of protein C from fraction IV of the Cohn process using immobilized metal affinity chromatography. (1997) (2)
Restricted addition of proviral DNA in target tissues of chickens infected with avian myeloblastosis virus. (1976) (2)
Transgenic Livestock as Drug Factories By introducing key human genes into mammals, biologists can induce dairy animals to produce therapeutic proteins in their milk (1997) (2)
Transgenic animals: “Great and small” (1992) (1)
Discussion: Delivery of Demineralized Bone Powder by Fibrin Sealant (1995) (1)
Homogeneity and complexity of avian oncornavirus proviral DNA determined by molecular hybridization (1977) (1)
Human Plasma Proteins from Transgenic Animal Bioreactors (1996) (1)
Gel compression considerations for chromatography scale-up for protein C purification. (1998) (1)
Viruses and Mammary Carcinoma (1978) (1)
Variant Creutzfeldt-Jakob disease and prions in the blood supply. (2004) (1)
Human plasma-derived media supplement supports antibody production by hybridoma cells (1992) (0)
Fabric covering and growth factor-containing compounds to promote enhanced wound healing (1991) (0)
Laminin-binding peptide fragments. (1987) (0)
Effect of Gamma Radiation on the Structural and Functional Integrity of IgG (2015) (0)
RNA ofSimian Sarcoma-Associated Virus Type1Produced in HumanTumorCells (1975) (0)
EXPRESSION OF A HETEROLOGOUSPOLYPEPTIDE IN MAMMARY TISSUE OFTRANSGENIC NON-HUMAN MAMMALSUSING ALONG WHEY ACDIC PROTEINPROMOTER (1998) (0)
Nucleic acid and protein studies of the Mason-Pfizer virus. (1975) (0)
Chromatographic process identification for protein C purification using frequency response analysis. (1997) (0)
P66. A novel process for sterilizing allografts using 50 kGy of gamma irradiation (2003) (0)
4868113 Recombinant DNA vector encoding human endothelial cell growth factor (1990) (0)
TRANSGENIC NONHUMAN MAMMALSPRODUCING FIBRINOGEN IN MILKANDMETHODS OF PRODUCING FIBRIN (2008) (0)
Methods for sterilizing preparations of urokinase (2003) (0)
Distribution ofDeoxyribonucleic Complementary totheRibonucleic Acid ofAvianMyeloblastosis Virus inTissues ofNormalandTumor-Bearing Chickens (1972) (0)
Diversity ofMammaryTumorViral GenesWithin theGenus Mus,theSpecies Musmusculus, andtheStrain C3H (1979) (0)
A MODEL OF AN ANTIBODY-PROTEIN COMPLEX (1988) (0)
A process for the preparation of biologically active vitamin K dependent proteins by recombinant methods (2006) (0)
Restricted Addition of ProviralDNA in Target Tissues of Chickens infected with Avian ~ ~ e l ~ b l a s t o s i s Virus (2005) (0)
Gel Compression Considerations for Chromatography Scale-Up for Protein C Purification (1997) (0)
Sealants supplemented tissue, production procedures and use. (1994) (0)
Transgenes, development and disease (2007) (0)
Opinion: Technologies for Purifying Blood Proteins With Therapeutic Applications: Current Status, Future Needs (1988) (0)
CORRELATION BETWEEN THE DEVELOPMENT OF MURINE MAMMARY CANCER AND THE SEGREGATION OF ENDOGENOUS GENES (1980) (0)
Immune Adsorption Chromatography for Protein Purification (1993) (0)
Method for producing vitamin K dependent proteins by recombinant methods biologically active (2006) (0)
Quantitative NAT for pathogen inactivation verification. (2004) (0)
NOVEL PATHOGEN INACTIVATION OF SOFT TISSUE ALLOGRAFTS USING OPTIMISED GAMMA IRRADIATION (2005) (0)

This paper list is powered by the following services:

Other Resources About William Drohan

en.wikipedia.org

What Schools Are Affiliated With William Drohan?

William Drohan is affiliated with the following schools: